United Therapeutics (UTHR) Cash from Operations (QoQ) (2009 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Cash from Operations (QoQ) (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn |
| 2 | AbbVie | 440.49 Bn | 433.92 Bn | 12.70 Bn |
| 3 | Merck | 365.81 Bn | 358.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.67 Bn | 258.98 Bn | 11.24 Bn |
| 5 | Pfizer | 158.99 Bn | 147.29 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.30 Bn | 20.77 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.54 Bn | 15.15 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.31% |
| Mar 31, 2026 | 33.82% |
| Dec 31, 2025 | -38.41% |
| Sep 30, 2025 | 193.22% |
| Jun 30, 2025 | -58.43% |
| Mar 31, 2025 | 35.17% |
| Dec 31, 2024 | -9.54% |
| Sep 30, 2024 | 62.45% |
| Jun 30, 2024 | -38.33% |
| Mar 31, 2024 | 149.83% |
| Dec 31, 2023 | -56.47% |
| Sep 30, 2023 | 225.68% |
| Jun 30, 2023 | -71.64% |
| Mar 31, 2023 | 192.36% |
| Dec 31, 2022 | -50.43% |
| Sep 30, 2022 | 103.62% |
| Jun 30, 2022 | -56.01% |
| Mar 31, 2022 | 65.35% |
| Dec 31, 2021 | -5.93% |
| Sep 30, 2021 | 25.24% |